Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Jack Latham

Haemonetics Corporation

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services, Inc.

Haemonetics Vascular Closure

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Metric
Company Name	Haemonetics Corporation	West Pharmaceutical Services, Inc.
Symbol	HAE	WST
MSH ID	COM:HAEMONETICS	COM:WESTPHARMA
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Medical - Instruments & Supplies	Medical - Instruments & Supplies
Country	US	US
Stage
Employee Count	3.66K	10.60K
Website	haemonetics.com	westpharma.com
LinkedIn	haemonetics
Founders

Metric
Market Cap	4.44B	23.41B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.31B	2.95B
Revenue (LTM)
Revenue (NTM)
Gross Profit	676.54M	1.13B
EBITDA	305.35M	875.70M
Operating Income	208.14M	676M
Net Income	117.56M	593.40M
EPS	2.32	7.98
Diluted EPS	2.29	7.88
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.53	0.38
Operating Profit Margin	0.14	0.23
EBITDA Margin	0.23	0.30
Net Profit Margin	0.10	0.20
Return on Equity	0.14	0.21
Return on Assets	0.06	0.16
Return on Capital Employed	0.10	0.22

COM:HAEMONETICS

Haemonetics Corporation

Last Close

85.43

22/11 21:00

Market Cap

4.44B

Beta: -

Volume Today

481.00K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	29.87	52.81
P/B Ratio	4.29	10.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.83	9.76
EV Multiple	16.29	34.90

Metric
Days Sales Outstanding	51.32	64.74
Days Payables Outstanding		44.24
Days Inventory Outstanding	213.51	87.15
Operating Cycle	268.64	150.56
Cash Conversion Cycle	246.97	104.66
Asset Turnover	0.60	0.82

Metric
Operating Cash Flow	181.75M	776.50M
Free Cash Flow	115.45M	414.50M
Cash Flow to Debt	0.23	3.31
Operating Cash Flow/Sales	0.16	0.26
Free Cash Flow Yield	0.03	0.01

Metric
Cash & Equivalents	178.80M	853.90M
Accounts Receivable	-24.19M	4M
Inventory	317.20M	434.70M
Goodwill	565.08M	108.50M
Debt to Capitalization	0.57	0.10
Debt to Assets	0.38	0.08
Current Ratio	3.28	3.70
Quick Ratio	2.33	2.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.01
R&D to Revenue	0.04	0.02
SG&A to Revenue